Jean-gabriel G. Fuzibet

Nice, FR 
Nice, FR 

Overview

Jean-gabriel Fuzibet practices practicing medicine in Nice, France.

Their clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Strongyloidiasis, and Rhabditida Infections.

They are actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 3 clinical trials.

Locations

Nice, France
Other Locations
Rennes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Identification of Genetic Factors Predisposing to Dysglobulinemia
Identification of Genetic Factors Predisposing to Dysglobulinemia
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Genetic
Study Phase: Not Applicable
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study
Enrollment Status: Completed
Publish Date: August 13, 2025
Intervention Type: Drug
Study Drug: Apixaban
Study Phase: Phase 3
Implication of the Antiapoptotic Protein BCL-B in the Pathogenesis of Multiple Myeloma
Implication of the Antiapoptotic Protein BCL-B in the Pathogenesis of Multiple Myeloma
Enrollment Status: Completed
Publish Date: January 26, 2024
View 2 Less Clinical Trials

13 Total Publications

Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.
Journal: American journal of hematology
Published: February 08, 2019

Frequently Asked Questions about Jean-gabriel G. Fuzibet

Is Jean-gabriel G. Fuzibet a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Jean-gabriel G. Fuzibet is classified as an Experienced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jean-gabriel G. Fuzibet participate in research or clinical trials?

Yes. Jean-gabriel G. Fuzibet has published 13 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Jean-gabriel G. Fuzibet's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Fuzibet's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile